Declaration of Dr. S. Jamal Mustafa
`Regarding U.S. Patent No. 6,645,513
`
`UNITED STATES PATENT AND TRADEMARKOFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`PETITION FOR INTER PARTES REVIEW
`OF U.S. PATENT NO.6,645,513
`
`DECLARATIONOF S. JAMAL MUSTAFA,Ph.D.
`
`L'OREAL USA,INC. EX. 1011
`
`

`

`Declaration of Dr. S. Jamal Mustafa
`Regarding U.S. Patent No. 6,645,513
`
`I, S. Jamal Mustafa, Ph.D., declare as follows:
`
`1.
`
`The opinions set forth below are based on my over 42 years of
`
`experience as an expert in biochemistry and pharmacology and on the review of
`
`materials discussed herein.
`
`I
`
`BACKGROUND AND QUALIFICATIONS
`
`2.
`
`My curriculum vitae (“CV”) (a copy of whichis attached) highlights
`
`my education, experience, and qualifications as an expert in biochemistry and
`
`pharmacology. Someofthe information relevant to this case is summarized
`
`below.
`
`3.
`
`[received a Bachelor of Science (B.S.) degree in Chemistry from
`
`Lucknow University in 1962, a Master of Science (M.S.) degree in Biochemistry
`
`from Lucknow University in 1965, and a Doctorate (Ph.D.) degree in Biochemistry
`
`from Lucknow University in 1970.
`
`4.
`
`I was an Assistant Dean for Research and Assistant Vice President for
`
`Research in the Health Sciences Center at West Virginia University (WVU)in
`
`Morgantown, WV,positions I have held since 2005 and 2008 until June 30, 2015,
`
`respectively. I am also a Professor in the Department of Physiology &
`
`Pharmacology of the WVU School of Medicine, and an Adjunct Professor in the
`
`WVU School of Pharmacy, and have been since 2005. Through these programs, I
`
`am teaching graduate, medical and pharmacy courses in pharmacology.
`
`

`

`Declaration of Dr. S. Jamal Mustafa
`Regarding U.S. Patent No. 6,645,513
`
`5.
`
`From 1980 to 2005, I worked as a Professor or Adjunct Professorin a
`
`numberof departments of the School of Medicine at East Carolina University,
`
`including the Heart Center and the Departments of Pharmacology, Surgery,
`
`Medicine, and Physiology. In the past, I have also taught pharmacology courses at
`
`the University of South Alabama College of Medicine, and East Carolina
`
`University School of Medicine after finishing my post-doctoral training at the
`
`University of Virginia, School of Medicine (1971-74).
`
`6.
`
`[have participated as Principal Investigator in over thirty grant-based
`
`research projects. My present research with the Health Sciences Center involves
`
`identifying and studying the role of adenosine receptors in normal and diseased
`
`tissues, and studying the roles of second messengersin the regulation of adenosine
`
`receptor expression, mostly in heart and lung.
`
`7.
`
`Professional honors that I have received while at WVU include the
`
`Chancellor’s Award for Outstanding Achievement in Research and Scholarly
`
`Activities in April 2013, the Robert C. Byrd Professorship in March, 2010, and the
`
`Award for Excellence in Research from School of Medicine in April, 2008. As
`
`further detailed in my CV, other Professional honors that I have received include:
`
`Lifetime Achievement Award in Research and Creative Activities from East
`
`Carolina University, June, 2003; First Award for Excellence in Basic Research
`
`from East Carolina University School of Medicine, May, 1997.
`
`3
`
`

`

`Declaration of Dr. S. Jamal Mustafa
`Regarding U.S. Patent No. 6,645,513
`
`8.
`
`I have authored or co-authored over 200 articles published in
`
`scientific journals on the subject of adenosine,its derivatives, or cellular activity
`
`related to adenosine receptors. In addition, I have contributed to at least thirty
`
`review articles and/or textbooks, and am on or have been on the Editorial Board of
`
`a numberof peer-reviewed journals, including Reactive Oxygen Species and
`
`American Journal ofPharmacology and Toxicology, Vascular Pharmacology, as
`
`well as many others.
`
`Il.
`
`COMPENSATION, PREVIOUS TESTIMONY, AND
`RELATIONSHIP TO THE PARTIES
`
`9.
`
`1am being compensated at an hourly rate of $ 350 for the time I spend
`
`studying materials and issues associated with this matter and for the time I spend
`
`providing testimony. This rate is my standard consulting rate. My compensationis
`not contingent upon the outcomeofthis matter.
`
`10.
`
`It is my understanding that University of Massachusettsis the
`
`assignee of the ‘513 patent. Prior to this matter, I have not worked for University
`
`of Massachusetts, and am aware ofno financial interest that I have in the
`
`University of Massachusetts.
`
`11.
`
`Il. MATERIALS CONSIDERED
`
`12.
`
`Ihave reviewed the following materials:
`
`

`

`Declaration of Dr. S. Jamal Mustafa
`Regarding U.S. Patent No. 6,645,513
`
`U.S. Patent No. 6,645,513 to Dobsonetai.
`
`
`
`
`
`
`
`No.
`
`1002
`
`1014
`
`1015
`
`1019
`
`
`
`
`
`
`
`
`Kathryn M.Neurathet al., AMP-Dependent Protein Kinase
`Alpha 2 Isoform Promotes Hypoxia-Induced VEGF Expression in
`HumanGlioblastoma, 53 Glia 733, 733-743 (2006).
`
`
`
`
`
`Geoffrey Burnstocket al., Purinergic Signaling in Healthy and
`Diseased Skin, 132 J. Invest. Dermatol 526, 526—546 (2012).
`
`
`
`RH. Koizumiet al., Adenosine Deaminase in Human Epidermis
`JSrom Healthy and Psoriatic Subjects, 275 Arch Dermatol Res 310,
`
`
`310-14 (1983).
`
`
`IV. Adenosine Monophosphate is an Angiogenic Factor
`
`
`13. Adenosine Monophosphate (AMP) is knownto be an angiogenic
`
`factor. (Ex. 1014). The property of AMP as an angiogenic factor is inherent and
`
`would not have changedovertime. In other words, the inherent function of AMP
`
`as an angiogenic factor has not changed since 1998.
`
`V.
`
`Adenosine Metabolizes in the Epidermis
`
`14.
`
`It is my understanding that human skin includes manylayers,
`
`including an outer, epidermal layer, which covers multiple inner layers (including
`
`the dermallayer). (Ex. 1002, col. 1, ll. 25-30). The ‘513 patent describes the skin
`
`as having “a surface layer, knownas the epidermis, and a deeper connective tissue
`
`layer, knownas the dermis.” (/d.)
`
`

`

`Declaration of Dr. S. Jamal Mustafa
`Regarding U.S. Patent No. 6,645,513
`
`15. Adenosine-metabolizing enzymesare ubiquitous and are foundin
`
`every livingcell, including cells in the epidermis. (Ex. 1015). Adenosinetopically
`
`applied to the epidermis can be metabolized and degraded to its metabolites
`
`(inosine, hypoxanthine), or taken up in the epidermal cells and converted to AMP,
`
`ADTand ATPetc.(/d., also Ex. 1019). As such,it is my opinion thatat least
`
`some of any concentration of adenosine that is topically applied to the epidermis
`
`will be metabolized by epidermal cells and not reach the dermal layer.
`
`16.
`
`I further declare that all statements made herein of my own
`
`knowledgeare true and that all statements made on information and belief are
`
`believed to be true, and further, that these statements were made with the
`
`knowledgethat willful false statements and like so made are punishable byfine or
`
`imprisonment, or both, under Section 1001 of Title 18 of the United States Code.
`
`Dated: Nbonet (S , 2018
`
`ws Vaan NMUc
`
`S. Jamal MUSTAFA,Ph.D.
`
`

`

`April 8, 2016
`
`CURRICULUM VITAE
`
`NAME:
`
`SOCIAL SECURITY NUMBER:
`
`MARITAL STATUS:
`
`CITIZENSHIP:
`
`BUSINESS ADDRESS:
`
`HOMEADDRESS:
`
`S. Jamal Mustafa
`
`Upon Request
`
`Married, three children
`
`American
`
`Robert C Byrd Professor ofPhysiology and
`Pharmacology and Basic Pharmaceutical Sciences
`WVUHealth Sciences Center
`2267 Health Sciences South
`PO Box 9104
`Morgantown WV 26506-9104
`Phone: (304) 293-1123
`FAX:
`(304) 293-3850
`E-mail: simustafa@hsc.wvu.edu
`http:/Avww.hsc.wvu.edu/ccrs/Investigators/mustafa.a
`sp
`
`203 Rivercrest Drive
`Morgantown, West Virginia 26508
`Phone: (304) 599-2330
`
`ACADEMIC QUALIFICATIONS:
`
`BS.
`MS.
`
`Ph.D.
`
`Major: Chemistry
`Biochemistry
`
`LucknowUniversity
`LucknowUniversity
`
`Biochemistry
`
`LucknowUniversity
`
`Postdoctoral Fellow
`
`Toxicology
`
`C.S.LR., New Delhi
`
`Postdoctoral Fellow
`
`Cardiovas. Physiol.
`
`Univ. of Virginia
`
`EMPLOYMENT:
`
`Pre doctoral Fellow
`
`Pre doctoral! Fellow
`
`Pre doctoral Fellow
`
`(Lucknow Univ.Res.
`Fellowship; 1 year) Dept.
`of Biochemistry; LucknowUniv.
`Lucknow,India
`
`(State C.S.1.R., Lucknow;
`1 year) Dept. of Biochemistry,
`LucknowUniv.Lucknow,India
`
`(I.C.M.R., New Delhi,
`1 1/2 years) Department of Biochem-
`istry, Lucknow Univ. Lucknow,
`India
`
`1962
`1965
`
`1969
`
`1970-71
`
`1971-74
`
`1965-1966
`
`1966-1967
`
`1967-1969
`
`

`

`April 8, 2016
`
`Postdoctoral Fellow
`
`Postdoctoral Fellow
`
`Assistant Professor
`
`Associate Professor
`
`Associate Professor
`
`Professor (Adjunct)
`
`Professor (Adjunct)
`
`Professor
`
`Professor (Adjunct)
`
`Professor (Adjunct)
`
`Professor (Adjunct)
`
`(C.S.LR., New Delhi, 1 1/2
`years) Industrial toxicology
`ResearchCenter, Lucknow,India
`
`(NIH;3 years) Dept. of Physi-
`ology, Univ. of Virginia
`MedicalSchool, Charlottesville,
`Virginia, USA
`
`Department of Pharmacology
`University of SouthAlabama
`College of Medicine
`Mobile, Alabama, USA
`
`Department of Pharmacology
`University of SouthAlabama
`College of Medicine
`Mobile, Alabama, USA
`
`Department of Pharmacology
`School of Medicine
`EastCarolinaUniversity
`Greenville, North Carolina, USA
`
`Department of Surgery
`School of Medicine
`EastCarolinaUniversity
`Greenville, North Carolina, USA
`
`Department of Medicine
`School of Medicine
`EastCarolinaUniversity
`Greenville, North Carolina, USA
`
`Department of Pharmacology
`School of Medicine
`EastCarolinaUniversity
`Greenville, North Carolina, USA
`
`Department of Physiology
`School of Medicine
`EastCarolinaUniversity
`Greenville, North Carolina, USA
`
`Cardiovascular Center
`School of Medicine
`EastCarolinaUniversity
`Greenville, North Carolina, USA
`
`Departmentof Pediatrics
`School of Medicine
`EastCarolinaUniversity
`Greenville, North Carolina, USA
`
`1970-1971
`
`1971-1974
`
`1974-1977
`
`1977-1980
`
`1980-1983
`
`1991-1992
`
`1991 - 1995
`
`1983 - 2005
`
`1996-2005
`
`1997-2005
`
`2003-2005
`
`Professor (Adjunct)
`
`Basic Pharmaceutical Sciences
`
`2005-to date
`
`

`

`April 8, 2016
`
`Professor
`
`School of Pharmacy
`Morgantown, West Virginia, USA
`
`Department of Physiology & Pharmacology
`School of Medicine
`West VirginiaUniversity
`Morgantown, West Virginia, USA
`
`Assistant Dean for Research,
`
`WVUHealth Sciences Center,
`Morgantown, West Virginia, USA
`
`Assistant Vice President
`for Research,
`
`WVU Health Sciences Center,
`Morgantown, West Virginia, USA
`
`2005-to date
`
`2005-to date
`
`2008- June 2015
`
`RESEARCH AND/OR PROFESSIONAL EXPERIENCE:37yearsin the following fields:
`
`2005-to date: Responsibilities as Assistant Dean and Vice President, HSC, West Virginia University:
`
`Coordinate the internal grants program whichallocates seed funds for new projects and bridge
`funding for ongoing research projects with lapses in external grant support, based on competition
`and merit.
`Represent the School of Medicine andits research programs on the Scientific Advisory Board
`currently charged with implementation of the Strategic Research Plan.
`Work with the Assistant Vice President and Associate Dean to coordinate the annual Van Liere
`Convocation and Research Day symposium forthe entire HSC.
`Advise basic scientists as well as junior and mid-career faculty in clinical departments with
`regards to research career development and application for NIH-K awards especially in the clinical
`departments.
`Organize drug discovery group at the WVU Health Sciences Center which is envisioned to
`eventually include faculty from the main university campus, scientists from NIOSH, BRNI and
`Mylan as well as faculty from the four component schools at health sciences.
`To assumea leadership role in promoting independent, interdisciplinary, and multidisciplinary
`research projects throughout Health Sciences with a special emphasis on the research expertise
`needed for health sciences to obtain several NIH program project awards,participate in the
`university’s plans to develop a Research Park, and expand our performancein intellectual property
`and patent acquisition.
`Selected HSC faculty for one day ‘Grant Writing Workshop’ for June, 2009 and then selected ten
`candidates from the list 30 or so faculty from SOM fora full ‘Grant Writing Workshop’ sponsored
`jointly by the Research Cororation and ouroffice.
`Work with Center for Cardiovascular and Respiratory Center for submission of the Cardiovascular
`COBRE application ($10 million) from SOM as a PI. Oversee and review the Centerfor
`Cardiovascular and Respiratory Sciences progress.
`Work with the Clinical Translational Science Award group for revising the application for October
`2010 deadline. Program Director of the Pilot Project section of the CTSA application.
`Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational
`Research [[DeA-CTRJ[U54] for September 2011 deadline. Program Director of the Pilot Grants
`Project.
`Oversee the Pilot Projects of the CTSI Partnership Funding Programs with University of
`Kentucky, Ohio State University and Indiana University.
`MemberofResearch Cabinet of the Research Corp., WVU.
`Represent the School of Medicine at the bi-monthly Research Assistant/Associate Deans meetings
`of the university coordinated by the WVU Vice President for Research and Economic
`Development.
`
`

`

`April 8, 2016
`
`e
`
`¢ Workwith the other Assistant Deans for Research and the AVP on developing an efficient and
`productive approachto pre-submission grant review especially for major federal grants being
`submitted by new junior investigators or in revised form by senior faculty to respond to Study
`Section critiques.
`.
`Signature approvalafter staff budget review on all grants and contracts being submitted from
`faculty in the School ofMedicine.
`Coordinate planning sessions for submission ofNIH program project grants (P01) and NIH
`training grants (T-32) in the area of cardiovascular and pulmonary sciences.
`Coordinate an internal review ofthe research performancefor specific basic science andclinical
`departments with a special focus on departments in the School ofMedicine.
`e Oversee the OLARfacilities on a routine basis and work closely with the Director. Chairingthe
`Animal Advisory Committee of the HSC.
`e Assist with the Research Corp, (RC)forall the Program to Stimulate Competitive Researchgrants
`for Health Sciences Center.
`Review the submission of Intellectual Property applications for the HSCto the office of
`Technology Transfer.
`* Oversee the PPG seed funding and obtain PPG with the Cancer Center group headed by John
`Barnett
`
`*
`
`*
`
`e
`
`1980 to date: Presently working on defining the second messenger systems(cyclic nucleotides, G proteins,
`phospholipase C, protein kinase C and calcium)in the activation of vascular and endothelial adenosine receptors in
`coronary artery. We are also studying the up and downregulation of the coronary adenosine receptor and the
`involvement of second messengersin this process. Weare trying to purify the A2 adenosine receptor from vascular
`smooth muscle, sequenceit and ultimately clone it. We might try to get a cDNAforthis protein through the cDNA
`library, which codes for an identical protein. We are also working with the human coronary tissueto identify the
`adenosine receptors and the second messengers in normal and diseased tissue.
`
`Further, ] am also involved in the role of adenosine in asthma. Weare using an allergic rabbit and mouse
`models of late phase asthma for this project. We have found that adenosine is without a response in normal rabbits
`but has a very severe bronchoconstriction in allergic rabbits. We have identified this receptor as A; through binding
`and isolated muscle bath studies. A similar response was found in our mouse model. Weare using these models to
`test the effectiveness of anti-asthma drugs.
`
`Weare conducting a similar study in humans and [ am working with a clinician to study the role of
`adenosine in asthma. We have challenged normalindividuals and asthma patients with adenosine and measured the
`chemotactic factors in the blood. Weare collecting the bronchiolar lavage fluids for measuring the levels of
`adenosine to determine if there is a correlation between adenosine and the bronchial reactivity. We are doing these
`similar experiments in allergic rabbits. Recently, we have developed a murine modelforallergic asthma for these
`studies due to the availability of genetically altered animals.
`
`1974-1980: During this period we have studied the role of nucleosides and prostaglandinsin various low
`flow states with special emphasis to adenosine. We havestudied the various metabolic factors involved in the
`regulation of blood flow to heart, brain and kidney and the effect of hypoxia (or varying oxygen tension) on the
`release of these vasoactive agents and the relationship with each other. Further, we have studied the molecular
`mechanismsofvasodilatation such as the involvementof a specific receptor for adenosine in the heart, brain and
`kidney. We have usedisolated cardiac muscle, vascular smooth muscle, Langendorf heart andisolated cells for
`some of these experimentsin order to demonstrate the involvement ofthese agents in the regulation of bloodflow.
`The studies on the demonstration of adenosine receptor are done in intact coronary muscle preparation andisolated
`perfused hearts and include the binding studies. Further, we have also studied the calcium blocking effect of several
`vasodilators in relation to adenosineusing intact dog modeland isolatedtissue preparations.
`
`1971-1974: During this period, | worked as an NIH Postdoctoral Trainee with Dr. Robert M. Berne in the
`Departmentof Physiology, University of Virginia Medical School, Charlottesville, Virginia and was engaged in the
`field of cardiovascular physiology related to nucleotide metabolism. Part of this work was related to the membrane
`transport phenomenonon the adenosine hypothesis for the regulation of coronary blood flow. Human red bloodcell
`
`10
`
`

`

`April 8, 2016
`
`ghosts were used as a model for transport studies for adenosine. These studies have also been done taking
`embryonic heart cells at various ages of the chick embryo. The intracellular adenosine concentration,it’s
`deaminated and phosphorylated derivatives were detected. Cell culture, electron microscopy, dual wavelength
`spectrophotometry and chromatographic techniques were employedin studying adenosine metabolism. In addition,
`the effect of coronary dilators like dipyridamole and aminophylline on the metabolism of adenosine under normal
`and hypoxic conditions were studied in cultured cardiac cells.
`
`1970-1971: During this period, I worked as a postdoctoral fellow with Dr. 8. V. Chandra at the
`IndustrialToxicologyResearchCenter, Lucknow.This period was mainly devoted to the fundamental problems of
`occupational diseasesrelated to metal toxicity, which was mainly centered on manganese poisoning. Thedisease,
`which occurs in the manganese miners,is primarily a neurological syndromesimilar to Parkinson's disease. These
`studies included the extraction and estimation of neurotransmitter substances (dopamine and nor epinephrine) and
`serotonin employing spectrophotofluorometric technique, metal estimation, enzymestudies, electrophoresis and
`CSFprotein and enzymestudies.
`
`1965-1969: This period allowed me to complete the research work for doctorate degree (Ph.D.) at the
`Department ofBiochemistry, LucknowUniversity, Lucknow with Dr. C. P. Tewari. This included mainly
`biochemicalstudiesrelated to nutrition, energy aspects of mitochondrial, neurochemistry, enzyme studies including
`purification and kinetic. More sophisticated techniques like immunochemistry; electrophoresis and
`ultra-centrifugation were applied to study the isoenzymes of adenosine deaminase from the cytoplasmic and
`mitochondrial fractions of the mouse brain. In addition to this, detailed sub cellular studies for adenosine deaminase
`have been conducted with the brain, liver and spleen including various methods for solubilization of the
`mitochondrial enzymes,
`
`Some workrelated to ammonia production in kidney has been done whichis not included in Ph.D.thesis.
`This paper emphasizes that the guanine and adenosine deaminases of kidney are indirectly involved and play a
`contributory role in acid-base regulation by ammonia metabolism.
`
`TEACHING EXPERIENCE:
`
`(i)
`
`(ii)
`
`(iii)
`
`(iv)
`
`(v)
`
`(vi)
`
`I have participated in lab-teaching of M. S. students during my Ph.D.period in the Departmentof
`Biochemistry, LucknowUniversity, Lucknow,India.
`
`I wasactively engaged in the teaching of cardiovascular physiology to medical and nursing
`students during my three year stay as a NIH (National Institute of Health, USA) postdoctoral
`fellow at the University at the University of Virginia, Department of Physiology, Charlottesville,
`Virginia, USA.
`
`While employed as an Assistant and Associate Professor of Pharmacologyat the University of
`South Alabama, College of Medicine, I was very actively engaged in the teaching of medical,
`nursing, graduate and physical therapy students at the medical school. My teaching assignments
`were in toxicology and industrial poisons, gastrointestinal pharmacology, neurochemistry, drug
`interactions, immunosuppressive drugs, biotransformation, non-narcotic analgesics, non-steroid
`anti-inflammatory drugs, endocrinology, chemotherapy and other related topics in pharmacology.
`
`At South Alabama, | offered an elective program in cardiovascular pharmacology/biochemistry
`and toxicology to senior medical students.
`
`] offered advance level graduate courses in Biochemical Pharmacology andCellular
`Pharmacologyat the University of South Alabama.
`
`I am presently involved in the teaching of Medical Pharmacology (conferences and lectures) and
`seniorelective in Cardiovascular Pharmacology.
`
`(vii)
`
`Presently, I am guiding the research offive postdoctoralfellows.
`
`11
`
`

`

`April 8, 2016
`
`(viii)
`
`Presently, I am offering a graduate course in Cardiovascular Pharmacology. This graduate
`teaching also includes the research seminarand thesis research for students leading toPh.D.
`
`(ix)
`
`(x)
`
`(xi)
`
`T am also involved in the teaching Pharmacology to Physician’s Assistants program.
`
`At WVU, I am teaching in Pharmacy course in Pharmacology (PCOL 744).
`
`At WVU,| am teachingin graduate level courses in Physiology and Pharmacology (PCOL793
`and PCOL 791).
`
`(xii)
`
`At WVU,I am teaching in M-2 course in Pharmacology (PCOL 761 and PCOL 770).
`
`(xiii)
`
`At WVU, I am teaching in Dental Pharmacology (PCOL 760).
`
`PROFESSIONAL HONORS:
`
`lL.
`
`Recipient of the ICMR (Indian Council of Medical Research, New Delhi). Junior Research Fellowship Pre-
`doctoral Award (1967-1969).
`
`Recipient of the CSIR (Council of Scientific and Industrial Research, New Delhi). Senior Research
`Postdoctoral Award (1970-1971).
`
`Postdoctoral trainee of the NIH (1971-1974).
`
`Listed as American Men and WomenofScience.
`
`Recipient of the Travel Award to attend the International Physiology Congress in Budapest, Hungary, 1980.
`
`Listed as Frontiers in Science and Technology in United States.
`
`FASEBVisiting Scientist at Elizabeth City State University, Elizabeth City, NC, March 24-25, 1988.
`
`Elected Fellow to the American Physiological Society-Cardiovascular Section, 1994.
`
`Recipient of the 1995 Helms Research Award from SigmaXi (the highest faculty award for
`outstanding researcher at East Carolina University).
`
`Elected Fellow to the American Heart Association - Circulation Council, 1995.
`
`Member, Editorial Board, American Journal of Physiology: Heart and Circulatory Physiology, 1995-1999.
`
`Distinguished Service Award from Association of Scientists of Indian Origin in America, 1996,
`
`Recipient of the First Award for Excellence in Basic Research from East Carolina University,School
`of Medicine, May, 1997
`
`Recipient of “Mario Toppo Distinguished Scientist Award”from Association of Scientists of Indian
`Origin in America, San Diego, CA, April 16,2000
`
`Recipient of the Life Time Achievement Award in Research and Creative Activities from East
`Carolina University, June, 2003
`
`Member, Editorial Board, American Journal of Physiology: Lung Cellular and Molecular Physiology,
`2003-2005.
`
`12
`
`

`

`April 8, 2016
`
`17.
`
`18.
`
`19.
`
`20.
`
`21.
`
`22.
`
`23.
`
`24,
`
`25.
`
`26.
`
`27.
`
`Member, Editorial Board and Associate Editor, Pulmonary Pharmacology and Therapeutics, 2004-to date.
`
`Member, Editorial Board, American Journal of Physiology: Heart and Circulatory Physiology, 2005-to date.
`
`Member, Editorial Board, Vascular Pharmacology, 2006-to date.
`
`Editorial Board, J. Pharmacol. Exp. Ther., 2010-to date.
`
`Recipient of the Award for Excellence in Research from West Virginia University, School of Medicine,
`April, 2008.
`
`Editor (with Connie Wilson) of Handbook of Experimental Pharmacology, Volume 200, Adenosine
`Receptors in Health and Disease, Springer- Verlag GmbH (2009).
`
`Recipient of the Robert C. Byrd Professorship from West Virginia University, March, 2010.
`
`Recipient of Chancellor's Award for Outstanding Achievement in Research and Scholarly Activities
`Health Sciences Center-West Virginia University, April2013.
`
`Elected as a Fellow of the American Heart Association, May 2013.
`
`MemberEditorial Board, American Journal of Pharmacology and Toxicology, 2015-to date.
`
`Editorial Board, Reactive Oxygen Species, 2016-to date.
`
`INTERNATIONAL MEETINGS ATTENDED AND OTHERINVITED SPEAKING ASSIGNMENTS:
`
`1.
`
`2.
`
`First World Congress on Micro circulation-Toronto, Canada, June, 1975 - Speaker.
`
`World Cell Culture Congress -Birmingham, Alabama, September, 1975 - Invited Speaker.
`
`International Symposium on Industrial Toxicology, Lucknow, India, November, 1975 - Invited Speaker.
`
`Symposium on "Trasylol and MyocardialInfarction," Frankfurt, West Germany, 1975 - InvitedSpeaker.
`
`International Symposium on the “Mechanismsof Vasodilatation," Antwerp, Belgium- July,
`1977 - Participant.
`
`International Symposium on the "Excitation - Contraction Coupling," Heidelberg, West Germany-July,
`1977-Participant.
`
`13th International Physiological Congress, Paris, France- July, 1977 - Speaker.
`
`International Conference on "Physiological and Regulatory Functions of Adenosine and Adenine
`Nucleotides," Banff, Canada- June 1978 - Invited Speaker.
`
`9th International Heart Congress -New Delhi, India- October, 1978 - Speaker.
`
`Visiting Guest Lecture of the Society of Biological Chemists of India at Lucknow,India, on the "Cellular
`Mechanisms of Coronary Flow Regulation by Adenosine" - November 1978.
`
`Satellite Symposium of the 14th International Physiological Congress on "Coronary Circulation" at Bad
`
`13
`
`

`

`April 8, 2016
`
`Nauheim, West Germany, July 1980 - Invited Speaker.
`
`Visiting Guest Lecturer of the Thorax center/Cardiovascular Research of the ErasmusUniversity,
`Rotterdam. Seminar Topic was “Adenosine and Coronary circulation," July 1980.
`
`14th International Physiological Congress, Budapest, Hungary, July 1980 - Speaker.
`
`8th International Congress of Pharmacology, Tokyo, Japan, July 1981 - Speaker.
`
`Visiting Guest Lecturer at the Department of Pharmacology, Niigata University School ofMedicine,
`Niigata, Japan, July 1981.
`
`Visiting Scientist at Second Department of Medicine, Faculty of Medicine, University of Tokyo, Japan,
`July 1981,
`
`Visiting Scientist at Chugai Pharmaceuticals Ltd., Tokyo, Japan, July 1981.
`
`International Symposium on “Physiology and Pharmacology of Adenosine Derivatives" Invited Speaker.
`Tokyo, Japan, July 1981.
`
`Visiting Guest Lecturer at the Department of Pharmacology, Faculty of Science, MahidolUniversity,
`Bangkok,Thailand, July 1981.
`
`Participantat the International Symposium on Adenosine - June 7-11, 1982, Charlottesville, Virginia, USA.
`
`11th International Heart Congress, London, England- July 1983 - Speaker.
`
`XIX Cardiology Congress, Argentina, September, 1983 - Speaker.
`
`Dilazep Meeting, Bombay and New Delhi, India, September, 1983 - Guest speaker.
`
`International Symposium on Calcium Entry Blockers and Tissue Protection -Rome, Italy, March 15-16,
`1984 - Speaker.
`
`Visiting Scientist of Council of Scientific and Industrial Research, New Delhi, India at Industrial
`Toxicology Research Center, Lucknow,India and Central Drug Research Institute, Lucknow,India.
`April-June 30, 1984.
`
`Invited Speaker of Departments of Medicine and Biochemistry, East Carolina University, Greenville, NC,
`Combined seminar series, February 5, 1985, Topic: "Biochemical Mechanismsfor the Regulation of
`Coronary Blood Flow".
`
`Invited Guest Speaker at Burroughs Welcome Foundation, Research Triangle Park, NC, February 13,1985,
`Topic: “Mechanisms of Coronary Flow Regulation by Adenosine”.
`
`Visiting Guest Seminar on “Calcium blocking activity of dilazep in isolated tissues" at DegussaPharma
`Gruppe, Frankfurt, West Germany, March 1985.
`
`Invited Guest Speakerat International Society for Heart Research (Indian Section) Lucknow,India, March,
`1985. Topic: "Calcium blocking activity of dilazep in comparison to standard calcium entry blockers in
`isolated tissues."
`
`Invited Guest Speaker at Rutgers University, New Brunswick, NJ, March 10, 1986, Topic: "Mechanism of
`Coronary Flow Regulation by Adenosine".
`
`17.
`
`18.
`
`19,
`
`20.
`
`21.
`
`22.
`
`23.
`
`24.
`
`25.
`
`26.
`
`27.
`
`28.
`
`29,
`
`30.
`
`14
`
`

`

`April 8, 2016
`
`31.
`
`32.
`
`33.
`
`34.
`
`35.
`
`36.
`
`37.
`
`38.
`
`39.
`
`40.
`
`41.
`
`42.
`
`43,
`
`44,
`
`45.
`
`46.
`
`47,
`
`48.
`
`Invited Speaker, Departmentof Physiology, East Carolina University Medical School, Greenville, NC May
`7, 1986, Topic: "Mechanisms of Coronary Flow Regulation”.
`
`Invited Speaker, Surgical Society of East Carolina University, School of Medicine, Greenville, NC, April
`15, 1987, Topic, "Adenosine receptors in the heart".
`
`Guest Speaker, Indian Pharmacological Society, Lucknow Branch at Central Drug ResearchInstitute,
`Lucknow,India, August 13, 1987, Topic "Mechanism of Action of Adenosine on Coronary Smooth
`Muscle".
`
`Invited Speaker, “Discussion Meeting onthe role of adenosine in pain perception and neuro-regulation of
`the cardiovascular system" sponsored by the Commissionofthe
`European Communities, Topic:
`“Adenosine Receptors in the Heart”at Pisa, Italy, December 18-19, 1987.
`
`FASEBVisiting Scientist, Elizabeth City State University, Elizabeth City, NC, Topic "Adenosine
`Receptors in the Heart", March 24-25, 1988.
`
`Guest Speaker, Ciba-Geigy Corporation, Summit, NJ, Topic "Relaxing Effects of Adenosine and its
`Analogs in Vascular Smooth Muscle”, June 1, 1988.
`
`Invited Speaker at the International Conference on Biomembranesin Health and Disease; November1-4,
`1988, Lucknow, India. Topic: "Adenosine Receptors in Vascular Smooth Muscle."
`
`Guest Speaker, Department of Physiology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. Topic:
`"Mechanisms of Coronary Flow Regulation by Adenosine”, July 22, 1989.
`
`Invited Speaker, Department of Pathology, School of Medicine, East Carolina University, Greenville, NC,
`March 14, 1990.
`
`4th International Symposium on Adenosine and Adenine Nucleotides at Lake Yamanaka, Japan, May
`13-17, 1990.
`
`Invited Speaker, Asta Medica, Frankfurt, Germany. Topic: "Effect of Azelastine and D-18024 on
`Allergen-Induced Airway Obstruction in Allergic Rabbits". July 8-10, 1991.
`
`Invited Speaker, Cytel Corp., Dan Diego, California. Topic: “Role of Adenosine in Asthma". March 16-
`18, 1992.
`
`Invited Speaker, Asta Medica, Frankfurt, Germany. Topic: "Role of Adenosine in Asthma". May 7-8, 1992.
`
`Participant at the XVth European Congress of Allergology and Clinical Immunology, Paris, May 10-15,
`1992
`
`Symposium Speakerat the Purines' 92 meeting. Topic: "Adenosine-receptor mediated
`bronchoconstriction". Milan, June 21-24, 1992.
`
`Symposium Speaker at Adenosine’ 92 Mexico meeting. Topic: “Bronchial Effects of Adenosine in
`Asthma". Ixtapa, Mexico, September 24-26, 1992,
`
`Participantat the XXXII Congress ofthe International Union of Physiological Sciences, August 1-6, 1993,
`Glasgow,Scotland.
`
`Invited Speaker at the Dept. of Physiology, Texas College of Osteopathic Medicine, Univ. ofNorth Texas,
`Health Sciences Center at Fort Worth, Fort Worth, Texas. Topic: "Mechanism(s) of Coronary Artery
`Relaxation by Adenosine". December2, 1993.
`
`

`

`April 8, 2016
`
`49.
`
`50.
`
`SI.
`
`52.
`
`53.
`
`34.
`
`55.
`
`56.
`
`57.
`
`58.
`
`Invited Speaker at the Dept. of Physiology, School of Medicine, East Carolina Univ., Greenville, NC.
`Topic: "Mechanism(s) of Coronary Artery Relaxation by Adenosine". March 15,1994
`
`Invited Speaker at the Dept. of Pharmacology, School of Medicine, Wright State Univ., Dayton, Ohio.
`Topic: "Mechanism(s) Of Coronary Artery Relaxation by Adenosine". April
`20, 1994,
`
`Guest Speakerat the 5th Intern, Sym. on Adenosine and Adenine Nucleotides, Philadelphia, PA. Topic:
`"Evidence for the Involvement of Nitric Oxide in Adenosine Receptor-Mediated Coronary Artery
`Relaxation". May 9-13, 1994.
`
`Session Chairman at the 5th Intern. Sym. on Adenosine and Adenine Nucleotides, Philadelphia, PA.
`Topic: "Coronary Vasodilatory and Cardioprotective Actions of Adenosine". May 9-13, 1994.
`
`Invited Speakerat the 2nd Messenger System: Molecular, Cellular and Behavioral Aspects. Trinidad and
`Tobago. Topic "Modulation of Protein Kinase C by Adenosine via A; Receptor and Pertussis Toxin
`Sensitive G Protein in Porcine Coronary Artery". June 16-17, 1994.
`
`Invited Speaker at the Department of Medical Physiology, TexasA&MUhniversity,